In a clinical trial lasting 8 weeks arthrofibrosis patients using the STAK gained on average 30° range of movement compared to patients receiving standard physiotherapy who gained only 8°.
“The STAK tool increases ROM and function whilst reducing stiffness and pain. This study shows the STAK tool would benefit clinical practice for a cost-effective and professional treatment for arthrofibrosis.”
1st Aug 2020
“In a clinical trial patients using the STAK increased their ROM on average
30° compared to receiving standard physiotherapy gained only 8°. The STAK patients also reported greatly reduced knee pain.”
9th Feb 2021
The device can be considered a cost-effective and valuable treatment following TKA. This is likely to increase the overall satisfaction rate and has potential to reduce the need for MUA.
7th July 2022
“Patients found the STAK very acceptable, and adherence to treatment was high. 93% considered that the STAK tool was wholly responsible for their change in knee range.”
1st May 2020
The systematic review indicates that Displacement Control (DCSR) devices are effective in increasing ROM in the treatment of knee stiffness.
March 2021
Significantly more effective than the current Usual Care. The STAK Tool improved knee joint flexion by 30.4° vs to 7.7° for Usual Care over an 8-week intervention and maintained after 12-months.
2020
“The STAK tool is an effective modality increasing ROM and reducing oedema, which can be used to offer home-based therapy to treat arthrofibrosis.”
2020
The STAK Orthopaedic Tool is a patented device. STAK is a registered Trademark ® of STAK Orthopaedics Ltd.
